Combination of Chemotherapy Plus RT and SHR-1210 to Treat Patients With ESCC

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2018
SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody. This is an openlabel,single center ,non-randomized ,Single Arm Exploratory Study . This clinical study is an investigator-initiated clinical trial(IIT). The objective of this study is to evaluate the efficacy and safety of radiation therapy combined with anti-PD-1 antibody SHR-1210 and chemotherapy in patients with Locally Advanced Esophageal Squamous Cell Carcinomas。
Epistemonikos ID: 08c2aaaa5b13aa9360d3756a73e3b0d633800a73
First added on: May 21, 2024